Mohamedtaki Abdulaziz Tejani

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad et al. · The Lancet Oncology · 2017 · 343 citations · Full text

Medicine, Oncology, Pharmacology +15

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding, Jia Fan, Do‐Youn Oh et al. · The Lancet Oncology · 2023 · 247 citations · Full text

Medicine, Oncology, Pharmacology +10

Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study

Jennifer S. Gewandter, L. Fan, Allison Magnuson et al. · Supportive Care in Cancer · 2013 · 181 citations

Medicine, Neurology, Oncology +14

Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation

Christian Probst, Adan Z. Becerra, Christopher T. Aquina et al. · Journal of the American College of Surgeons · 2015 · 180 citations · Full text

Medicine, Oncology, Surgery +17

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy

Vincent Chung, Shannon McDonough, Philip A. Philip et al. · JAMA Oncology · 2016 · 177 citations · Full text

Medicine, Oncology, Pharmacology +17